Endostar
Trials 67 · started per year
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-12-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Simcere Zaiming Announces Inclusion of Enzeshu® (Suvemcitug for Injection) in China’s 2025 National Medical Insurance Drug List simcere.com ↗
Another key product of Simcere Zaiming, Endostar® (Recombinant Human Endostatin Injection), has also been successfully transitioned to the conventional (non-negotiated) category of the National Medical Insurance Drug List. |
| 2023-06-06 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Simcere Zaiming showcases the latest R&D progress on its debut at 2023 ASCO annual meeting simcere.com ↗
In the real-world scenario, endostatin combination with PD-1 antibody plus chemotherapy obtained encouraging efficacy and favorable safety in advanced or metastatic NSCLC. |
| 2022-06-07 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Latest Clinical Data regarding ENDOSTAR and Trilaciclib Presented at the 2022 ASCO simcere.com ↗
ORR and DCR was 53% and 93% in Cohort 1 (CR, 0; PR, 8; SD, 6; PD,1) and 39% and 86% in Cohort 2 (CR 0; PR 11; SD, 13; PD, 4), respectively. |
| 2021-05-26 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Simcere Will Announce Progress of Multiple Clinical Research on Antitumor Drugs at the 2021 ASCO Annual Meeting Endostar®（Recombinant Human Endostatin Injection） Envafolimab (KNO35) simcere.com ↗
The ORR, DCR and median PFS were 34%, 73% and 8.2 (95% CI 6.0-13.7) months, respectively. |
All press releases naming this drug 6 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 74 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Endostar | “This single-arm pilot study tries to invesitgate how well giving icotinib with rh-endostatin (Endostar®) works in treating patients with advanced stage non-small cell lung...” NCT02375022 ↗74“The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer...” NCT02283476 ↗ “Camrelizumab (SHR-1210) Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous Non-small Cell Lung Cancer (NSCLC)” NCT04303130 ↗ “Rh-Endostatin (Endostar®) Continuous Intravenous Infusion” NCT03706703 ↗ |
| Known as | Endostar (a recombinant human endostatin) | “Endostar (a recombinant human endostatin)” NCT00853684 ↗ |
| Known as | human recombinant endostatin | “Endostar (human recombinant endostatin)” NCT02513355 ↗ |
| Known as | recombinant human endostatin | “NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid)...” PMID 41014160 ↗ Nov 20258“To evaluate the effectiveness, safety and tolerability of Endostar (recombinant human endostatin) combined with AI chemotherapy” NCT04699214 ↗ “Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.” NCT02513342 ↗ “Endostar ® (recombinant human endostatin) continuous intravenous infusion” NCT02749526 ↗ “endostar (recombinant human endostatin)” NCT00842491 ↗ “Endostar (Recombinant Human Endostatin)” NCT00813449 ↗ “recombinant human endostatin (Endostar)” NCT05574998 ↗ “Recombinant human endostatin (Endostar)” NCT06965231 ↗ “Recombinant Human Endostatin(Endostar)” NCT00813137 ↗ |
| Known as | Recombinant Human Endostatin Injection | “Endostar(Recombinant Human Endostatin Injection)” NCT00708812 ↗ |
| Known as | rh recombinant endostatin | “Endostar(rh recombinant endostatin) plus Docetaxel” NCT00813332 ↗ |
| Known as | Rh-endostatin | “This single-arm pilot study tries to invesitgate how well giving icotinib with rh-endostatin (Endostar®) works in treating patients with advanced stage non-small cell lung...” NCT02375022 ↗4“NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid)...” PMID 41014160 ↗ Nov 2025 “The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer...” NCT02283476 ↗ “Endostar™ (rh-endostatin, YH-16) is a new recombinant human endostatin developed by Medgenn Bioengineering Co. Ltd., Yantai, Shandong, P.R.China.” PMID 21108883 ↗ Aug 2005 “Rh-Endostatin (Endostar®) Continuous Intravenous Infusion” NCT03706703 ↗ |
| Known as | Rh-endostatin Injection | “Endostar® (Rh-endostatin Injection) may have anti-tumor activity by against vascular endothelial growth factor for initial treatment.” NCT00912392 ↗ |
| Known as | YH-16 | “Endostar™ (rh-endostatin, YH-16) is a new recombinant human endostatin developed by Medgenn Bioengineering Co. Ltd., Yantai, Shandong, P.R.China.” PMID 21108883 ↗ Aug 2005 |
| Action | Inhibit | “a inhibitor of angiogenesis” NCT00595972 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Endostatin” NCT00813137 ↗ |
| Route | Intravenous | “Endostar 15mg iv drip D1\~7, D15\~21” NCT00813137 ↗ |